Research ExplorerPublications1,25-dihydroxyvitamin-D3 but not the clinically applied mark...

1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation

Standard

1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation. / Peter, Katrin; Siska, Peter J; Roider, Tobias; Matos, Carina; Bruns, Heiko; Renner, Kathrin; Singer, Katrin; Weber, Daniela; Güllstorf, Martina; Kröger, Nicolaus; Wolff, Daniel; Herr, Wolfgang; Ayuk, Francis; Holler, Ernst; Stark, Klaus; Heid, Iris M; Kreutz, Marina.

In: BONE MARROW TRANSPL, Vol. 56, No. 2, 02.2021, p. 419-433.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Peter, K, Siska, PJ, Roider, T, Matos, C, Bruns, H, Renner, K, Singer, K, Weber, D, Güllstorf, M, Kröger, N, Wolff, D, Herr, W, Ayuk, F, Holler, E, Stark, K, Heid, IM & Kreutz, M 2021, '1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation', BONE MARROW TRANSPL, vol. 56, no. 2, pp. 419-433. https://doi.org/10.1038/s41409-020-01031-w

APA

Peter, K., Siska, P. J., Roider, T., Matos, C., Bruns, H., Renner, K., Singer, K., Weber, D., Güllstorf, M., Kröger, N., Wolff, D., Herr, W., Ayuk, F., Holler, E., Stark, K., Heid, I. M., & Kreutz, M. (2021). 1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation. BONE MARROW TRANSPL, 56(2), 419-433. https://doi.org/10.1038/s41409-020-01031-w

Vancouver

Peter K, Siska PJ, Roider T, Matos C, Bruns H, Renner K et al. 1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation. BONE MARROW TRANSPL. 2021 Feb;56(2):419-433. https://doi.org/10.1038/s41409-020-01031-w

Bibtex

@article{d63723518be14e179237baa606a2c843,
title = "1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation",
abstract = "The serum level of 25-hydroxyvitamin-D3 is accepted as marker for a person's vitamin D status but its role for the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is controversially discussed. The impact of 1,25-dihydroxyvitamin-D3 on HSCT outcome, however, has never been studied. In a discovery cohort of 143 HSCT patients we repeatedly (day -16 to 100) measured 1,25-dihydroxyvitamin-D3 and in comparison the well-established marker for serum vitamin D status 25-hydroxyvitamin-D3. Only lower 1,25-dihydroxyvitamin-D3 levels around HSCT (day -2 to 7, peritransplant) were significantly associated with higher 1-year treatment-related mortality (TRM) risk (Mann-Whitney U test, P = 0.001). This was confirmed by Cox-model regression without and with adjustment for baseline risk factors and severe acute Graft-versus-Host disease (aGvHD; unadjusted P = 0.001, adjusted P = 0.005). The optimal threshold for 1,25-dihydroxyvitamin-D3 to identify patients at high risk was 139.5 pM. Also in three replication cohorts consisting of altogether 365 patients 1,25-dihydroxyvitamin-D3 levels below 139.5 pM had a 3.3-fold increased risk of TRM independent of severe aGvHD compared to patients above 139.5 pM (Cox-model unadjusted P < 0.0005, adjusted P = 0.001). Our data highlight peritransplant 1,25-dihydroxyvitamin-D3 levels but not the commonly monitored 25-hydroxyvitamin-D3 levels as potent predictor of 1-year TRM and suggest to monitor both vitamin D metabolites in HSCT patients.",
author = "Katrin Peter and Siska, {Peter J} and Tobias Roider and Carina Matos and Heiko Bruns and Kathrin Renner and Katrin Singer and Daniela Weber and Martina G{\"u}llstorf and Nicolaus Kr{\"o}ger and Daniel Wolff and Wolfgang Herr and Francis Ayuk and Ernst Holler and Klaus Stark and Heid, {Iris M} and Marina Kreutz",
year = "2021",
month = feb,
doi = "10.1038/s41409-020-01031-w",
language = "English",
volume = "56",
pages = "419--433",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - 1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation

AU - Peter, Katrin

AU - Siska, Peter J

AU - Roider, Tobias

AU - Matos, Carina

AU - Bruns, Heiko

AU - Renner, Kathrin

AU - Singer, Katrin

AU - Weber, Daniela

AU - Güllstorf, Martina

AU - Kröger, Nicolaus

AU - Wolff, Daniel

AU - Herr, Wolfgang

AU - Ayuk, Francis

AU - Holler, Ernst

AU - Stark, Klaus

AU - Heid, Iris M

AU - Kreutz, Marina

PY - 2021/2

Y1 - 2021/2

N2 - The serum level of 25-hydroxyvitamin-D3 is accepted as marker for a person's vitamin D status but its role for the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is controversially discussed. The impact of 1,25-dihydroxyvitamin-D3 on HSCT outcome, however, has never been studied. In a discovery cohort of 143 HSCT patients we repeatedly (day -16 to 100) measured 1,25-dihydroxyvitamin-D3 and in comparison the well-established marker for serum vitamin D status 25-hydroxyvitamin-D3. Only lower 1,25-dihydroxyvitamin-D3 levels around HSCT (day -2 to 7, peritransplant) were significantly associated with higher 1-year treatment-related mortality (TRM) risk (Mann-Whitney U test, P = 0.001). This was confirmed by Cox-model regression without and with adjustment for baseline risk factors and severe acute Graft-versus-Host disease (aGvHD; unadjusted P = 0.001, adjusted P = 0.005). The optimal threshold for 1,25-dihydroxyvitamin-D3 to identify patients at high risk was 139.5 pM. Also in three replication cohorts consisting of altogether 365 patients 1,25-dihydroxyvitamin-D3 levels below 139.5 pM had a 3.3-fold increased risk of TRM independent of severe aGvHD compared to patients above 139.5 pM (Cox-model unadjusted P < 0.0005, adjusted P = 0.001). Our data highlight peritransplant 1,25-dihydroxyvitamin-D3 levels but not the commonly monitored 25-hydroxyvitamin-D3 levels as potent predictor of 1-year TRM and suggest to monitor both vitamin D metabolites in HSCT patients.

AB - The serum level of 25-hydroxyvitamin-D3 is accepted as marker for a person's vitamin D status but its role for the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is controversially discussed. The impact of 1,25-dihydroxyvitamin-D3 on HSCT outcome, however, has never been studied. In a discovery cohort of 143 HSCT patients we repeatedly (day -16 to 100) measured 1,25-dihydroxyvitamin-D3 and in comparison the well-established marker for serum vitamin D status 25-hydroxyvitamin-D3. Only lower 1,25-dihydroxyvitamin-D3 levels around HSCT (day -2 to 7, peritransplant) were significantly associated with higher 1-year treatment-related mortality (TRM) risk (Mann-Whitney U test, P = 0.001). This was confirmed by Cox-model regression without and with adjustment for baseline risk factors and severe acute Graft-versus-Host disease (aGvHD; unadjusted P = 0.001, adjusted P = 0.005). The optimal threshold for 1,25-dihydroxyvitamin-D3 to identify patients at high risk was 139.5 pM. Also in three replication cohorts consisting of altogether 365 patients 1,25-dihydroxyvitamin-D3 levels below 139.5 pM had a 3.3-fold increased risk of TRM independent of severe aGvHD compared to patients above 139.5 pM (Cox-model unadjusted P < 0.0005, adjusted P = 0.001). Our data highlight peritransplant 1,25-dihydroxyvitamin-D3 levels but not the commonly monitored 25-hydroxyvitamin-D3 levels as potent predictor of 1-year TRM and suggest to monitor both vitamin D metabolites in HSCT patients.

U2 - 10.1038/s41409-020-01031-w

DO - 10.1038/s41409-020-01031-w

M3 - SCORING: Journal article

C2 - 32855442

VL - 56

SP - 419

EP - 433

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

ER -